EMAC4008

EMAC4008 is a small molecule sunitinib analogue and an isatin-dihydropyrazole derivative developed as a potential antineoplastic agent, specifically for the treatment of pancreatic cancer. It belongs to a series of compounds designed to inhibit multiple receptor tyrosine kinases (RTKs), mimicking the mechanism of sunitinib but with potentially improved activity or selectivity. In preclinical studies, EMAC4008 has been evaluated for its ability to reduce cell viability, inhibit colony formation, and suppress cell migration in human pancreatic adenocarcinoma cell lines such as MIA PaCa-2 and PANC-1. These effects have been observed under both normoxic and hypoxic conditions, the latter being a common feature of the pancreatic tumor microenvironment that contributes to chemoresistance. The compound was developed by researchers at the University of Genoa as part of an effort to create more effective targeted therapies for recalcitrant cancers.